Please login to the form below

Not currently logged in
Email:
Password:

Final data shows CureVac’s COVID-19 vaccine is only 48% effective

New data shows slight improvement over previously reported 47% overall efficacy in interim analysis

A final analysis of a phase 2b/3 study of CureVac’s COVID-19 vaccine candidate CVnCoV demonstrated 48% overall efficacy, only a slight improvement on the previously reported 47% efficacy.

In June, CureVac reported that its first-generation mRNA vaccine candidate proved to only be 47% effective following an interim analysis of data from the pivotal HERALD study of approximately 40,000 participants.

In the final analysis, CureVac noted a higher overall efficacy among participants who are 18 to 60 years of age, with an efficacy of 53% against disease of any severity across all 15 identified variants in this population.

Protection against moderate-to-severe disease was found to be 77% effective, with the vaccine providing 100% protection against hospitalisation or death in the same age group.

For participants over 60 years of age – representing 9% of the analysed cases – the available data did not enable a statistically significant determination of efficacy, CureVac said in a statement.

Out of the 228 cases assessed in the final analysis, 204 were sequenced to identify the specific variant that caused the infection.

Investigators found that approximately 86% of these cases were caused by variants of concern and variants of interest. Only 3% of cases were attributable to the original SARS-CoV-2 virus, while the remaining 11% were caused by ‘less explored’ strains.

The study is set to continue to complete follow-up analyses for trial participants, while the available data has already been communicated to the European Medicines Agency (EMA).

“In the current context of an increasingly diverse environment of COVID-19 variants, and with very little residual prevalence of the original strain, we are confident that the HERALD study offers clinically relevant data regarding the effect of emerging variants on vaccine efficacy,” said Franz-Werner Haas, chief executive officer of CureVac.

Along with its first-generation mRNA COVID-19 vaccine, CureVac has partnered with GlaxoSmithKline (GSK) to develop the next generation of mRNA-based COVID-19 vaccines.

The deal is focused on developing a novel mRNA-based COVID-19 vaccine candidate, by using multivalent and monovalent approaches.

The next-generation vaccine will aim to offer broader protection against newly emerging variants, which have been reported to have the potential to reduce the efficacy of first-generation mRNA jabs.

Article by
Lucy Parsons

1st July 2021

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
nzyme

The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...